- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02381587
the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients (HAS)
Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome
sjogren syndrome is an autoimmune disease that mainly affects the Salivary glands and Lacrimal gland In addition to the effects of this disease is characterized by overall systemic Muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. In addition recent studies have shown that patients are at increased risk of the disease up to 2 cardiac events and stroke events Hydroxychloroquine is an RHEUMATIC DISEASE PROCESS SUPPRESSANTS-ANTIMALARIALS used to treat anti-inflammatory rheumatic diseases in many first-line treatment is sjogren syndrome.
A recent study of the treatment in Hydroxychloroquine effect on lipid profile sjogren syndrome patients showed a reduction in total cholesterol levels and increase in HDL. Further studies of the impact made Hydroxychloroquine systemic lupus patients erythematosus (SLE) showed in Atherosclerosis and morbidity and mortality reduction in cardiovascular. Studies of patients with rheumatoid arthritis (RA) demonstrated reduced risk of developing diabetes and improved lipid profile Research Goals valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Research Goals Valuate The effect of HCQ treatment in cardiovascular patients with primary sjogren syndrome Research Methods The study will included patients that diagnosed with sjogren syndrome and was treated in Meir Medical center during the years 2003-2014 During the study will collect information on confounding factors , Risk factors include cardiovascular acceptable such as diabetes, dyslipidemia, high blood pressure and the like, central nervous system involvement and steroid use
Study outcome will be one of the follow:
- Thrombosis of peripheral veins
- Arterial cardiovascular events
- Cardiac events (myocardial infarction
- Stroke (stroke and TIA)
4. Venous thrombosis events 5. Pulmonary embolism In the study will be 500 patients
Inclusion criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
Type d'étude
Inscription (Anticipé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- 18 years old
- Both sexes
- Patients that diagnosis in sjogren in treated in Meir Medical center in the years 2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion Criteria:
- Minors and special populations
- Patients that treated in Hydroxychloroquine at less than a month.
- Patient that participate in clinical trial and treat with investigational product
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Arterial cardiovascular events
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Cardiac events (myocardial infarction
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Thrombosis of peripheral veins
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Stroke (stroke and TIA)
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Venous thrombosis events
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Pulmonary embolism
Délai: 15 years since the first dose of hydroxychloroquine
|
15 years since the first dose of hydroxychloroquine
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies du système immunitaire
- Maladies auto-immunes
- Maladies oculaires
- Maladie
- Maladies articulaires
- Maladies musculo-squelettiques
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Arthrite
- Maladies stomatognathiques
- Maladies de la bouche
- Maladies de l'appareil lacrymal
- Arthrite, rhumatoïde
- Xérostomie
- Maladies des glandes salivaires
- Syndromes de sécheresse oculaire
- Maladies cardiovasculaires
- Syndrome
- Le syndrome de Sjogren
Autres numéros d'identification d'étude
- HCQ and sjogren
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Retrospective study
-
Apple Inc.Stanford UniversityComplétéFibrillation auriculaire | Arythmies cardiaques | Flutter auriculaireÉtats-Unis
-
Radicle ScienceComplétéLa dépression | La douleur | Dormir | AnxiétéÉtats-Unis
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutementMaladies du cerveau | Troubles du mouvement | Maladies neurodégénératives | Paralysie supranucléaire progressivePays-Bas
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutementMaladies du cerveau | Maladies du système nerveux central | Maladies du système nerveux | Maladie de Parkinson | Troubles parkinsoniens | Maladies des noyaux gris centraux | Troubles du mouvement | Maladies neurodégénérativesPays-Bas
-
Radicle ScienceComplété
-
Radicle ScienceActif, ne recrute pas
-
Digisight Technologies, Inc.InconnueLa rétinopathie diabétique | Dégénérescence maculaire liée à l'âge | MétamorphopsieÉtats-Unis
-
St. Joseph's Healthcare HamiltonSuspendu
-
University of MichiganComplété